From: Gene expression and adaptive noncoding changes during human evolution
Set | Collection | # genes | r_rb | SE(r_rb) |
---|---|---|---|---|
chr17q11 | C1:All | 66 | 0.88 | 0.021 |
chr12q13 | C1:All | 152 | 0.84 | 0.026 |
NIKOLSKY BREAST CANCER 17Q11 Q21 AMPLICON | C2:CGP | 80 | 0.84 | 0.033 |
chr17q21 | C1:All | 164 | 0.69 | 0.033 |
chr4q21 | C1:All | 61 | 0.62 | 0.066 |
chr1p13 | C1:All | 79 | 0.59 | 0.06 |
GNF2 DNM1 | C4:CGN | 63 | 0.41 | 0.046 |
RICKMAN HEAD AND NECK CANCER A | C2:CGP | 77 | 0.34 | 0.06 |
LEIN NEURON MARKERS | C2:CGP | 50 | 0.34 | 0.052 |
CAHOY NEURONAL | C6:All | 84 | 0.33 | 0.053 |
GCM MAP1B | C4:CGN | 53 | 0.33 | 0.076 |
ANASTASSIOU CANCER MESENCHYMAL TRANSITION SIGNATURE | C2:CGP | 53 | 0.33 | 0.069 |
SABATES COLORECTAL ADENOMA UP | C2:CGP | 86 | 0.33 | 0.049 |
GNF2 CCNA2 | C4:CGN | 52 | 0.32 | 0.065 |
KRAS.KIDNEY UP.V1 UP | C6:All | 113 | 0.32 | 0.047 |
VOLTAGE GATED CATION CHANNEL ACTIVITY | C5:MF | 57 | 0.31 | 0.061 |
NAKAYAMA SOFT TISSUE TUMORS PCA2 UP | C2:CGP | 71 | 0.31 | 0.053 |
GCM MAPK10 | C4:CGN | 71 | 0.31 | 0.059 |
CERVERA SDHB TARGETS 1 UP | C2:CGP | 95 | 0.3 | 0.052 |
VOLTAGE GATED CHANNEL ACTIVITY | C5:MF | 63 | 0.3 | 0.058 |